Galactose receptor-mediated hepatic targeting system: engineering of quinary cationic liposomes for resveratrol delivery against hepatic steatosis
Zhi-Jie Liang, Jinzhuai Li, Shuying Luo, Shaorong Li, Kun Zhao, Hongmian Jiang, Yu‐Che Ou, Juan Zhong, Lifeng Luo, Huali Huang, Yingying Li
Abstract
unmodified LNPs). In NAFLD mouse models, Gal-LNP-RSV reduced hepatic lipid accumulation and serum alanine aminotransferase/aspartate aminotransferase levels by 48.3% and 58.7%/49.3%, respectively, outperforming free RSV in both aspects. These findings underscore the potential of Gal-LNPs as a transformative means of overcoming RSV's pharmacokinetic barriers, enabling the precise activation of intracellular targets while restoring metabolic and redox homeostasis. This work provides a robust framework for developing targeted nanotherapeutics against NAFLD, bridging the divide between preclinical efficacy and clinical application.